Our solution aims to optimize and accelerate clinical trials for the development of drugs that treat Central Nervous System (CNS) diseases such as Parkinson’s & Alzheimer’s Disease (PD, AD), Multiple sclerosis (MS)…
FeetMe Research app achieves this by removing bias in the data, decreasing sample size variability, and increasing sensitivity to change with real word data.
The FeetMe solution (HIPAA and GDPR compliant) is a personal gait lab everywhere anywhere to build mobility biomarkers based on real-world data.
It is now possible to reduce the number of years between the identification of the target and the arrival of an approved drug on the market — a period of time which has lengthened in recent years, as has the size of the samples.
Our special measuring techniques are one of the reasons for the faster pace. Digital biomarkers allow participants to be measured much more frequently. Additionally, our clinical outcome assessment measures a very high resolution scale for a specific symptom, which reveals clinically meaningful symptom changes.
View and collect real-world data
Benefit from high patient compliance
Acquire a digital mobility report with a medical grade tool
Experience secure messaging
Benefit from a reinforced city-hospital link and a decongestion of hospitals
Seamless experience
Easy to use
Suited for fragile participants or participants unable to move
Avoid the frustration linked to the remoteness of the investigation center and the high frequency of visits
Uncomplicated procedures and protocols
Short monitoring time
“We need powerful tools that enable real-world collection of data. FeetMe® Monitor Insoles and FeetMe Rehabilitation App provide the same level of high quality data as a gait lab but much easier and everywhere!”
“Data captured in clinical settings in gait labs with the use of optoelectronic systems, are limited because the data does not represent the real-life environment.”
"In Parkinson's disease, the clinical environment can have an impact on the patient's performance: appearance or disappearance of paroxysmal symptoms"
